These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21996130)

  • 1. The whey fermentation product malleable protein matrix decreases TAG concentrations in patients with the metabolic syndrome: a randomised placebo-controlled trial.
    Gouni-Berthold I; Schulte DM; Krone W; Lapointe JF; Lemieux P; Predel HG; Berthold HK
    Br J Nutr; 2012 Jun; 107(11):1694-706. PubMed ID: 21996130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The whey fermentation product malleable protein matrix decreases triglyceride concentrations in subjects with hypercholesterolemia: a randomized placebo-controlled trial.
    Berthold HK; Schulte DM; Lapointe JF; Lemieux P; Krone W; Gouni-Berthold I
    J Dairy Sci; 2011 Feb; 94(2):589-601. PubMed ID: 21257028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.
    Dawczynski C; Massey KA; Ness C; Kiehntopf M; Stepanow S; Platzer M; Grün M; Nicolaou A; Jahreis G
    Clin Nutr; 2013 Oct; 32(5):686-96. PubMed ID: 23332800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory function of a malleable protein matrix as a novel fermented whey product on features defining the metabolic syndrome.
    Beaulieu J; Millette E; Trottier E; Précourt LP; Dupont C; Lemieux P
    J Med Food; 2010 Jun; 13(3):509-19. PubMed ID: 20406141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial.
    Ivey KL; Hodgson JM; Kerr DA; Thompson PL; Stojceski B; Prince RL
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):46-51. PubMed ID: 25171898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension.
    Lee YM; Skurk T; Hennig M; Hauner H
    Eur J Nutr; 2007 Feb; 46(1):21-7. PubMed ID: 17180485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of daily fortified yogurt consumption on weight loss in adults with metabolic syndrome: A 10-week randomized controlled trial.
    Mohammadi-Sartang M; Bellissimo N; Totosy de Zepetnek JO; Brett NR; Mazloomi SM; Fararouie M; Bedeltavana A; Famouri M; Mazloom Z
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):565-574. PubMed ID: 29724529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-fat milk consumption on metabolic and atherogenic biomarkers in Korean adults with the metabolic syndrome: a randomised controlled trial.
    Lee YJ; Seo JA; Yoon T; Seo I; Lee JH; Im D; Lee JH; Bahn KN; Ham HS; Jeong SA; Kang TS; Ahn JH; Kim DH; Nam GE; Kim NH
    J Hum Nutr Diet; 2016 Aug; 29(4):477-86. PubMed ID: 26945812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome.
    Azadbakht L; Mirmiran P; Esmaillzadeh A; Azizi T; Azizi F
    Diabetes Care; 2005 Dec; 28(12):2823-31. PubMed ID: 16306540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whey protein lowers systolic blood pressure and Ca-caseinate reduces serum TAG after a high-fat meal in mildly hypertensive adults.
    Fekete ÁA; Giromini C; Chatzidiakou Y; Givens DI; Lovegrove JA
    Sci Rep; 2018 Mar; 8(1):5026. PubMed ID: 29568003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different fractions of whey protein on postprandial lipid and hormone responses in type 2 diabetes.
    Mortensen LS; Holmer-Jensen J; Hartvigsen ML; Jensen VK; Astrup A; de Vrese M; Holst JJ; Thomsen C; Hermansen K
    Eur J Clin Nutr; 2012 Jul; 66(7):799-805. PubMed ID: 22588635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a low-fat, high-protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors.
    Claessens M; van Baak MA; Monsheimer S; Saris WH
    Int J Obes (Lond); 2009 Mar; 33(3):296-304. PubMed ID: 19153580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of increased calcium consumption from fat-free milk in an energy-restricted diet on the metabolic syndrome and cardiometabolic outcomes in adults with type 2 diabetes mellitus: a randomised cross-over clinical trial.
    Gomes JMG; Costa JDA; Alfenas RCG
    Br J Nutr; 2018 Feb; 119(4):422-430. PubMed ID: 29498351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a breakfast yoghurt, with additional total whey protein or caseinomacropeptide-depleted alpha-lactalbumin-enriched whey protein, on diet-induced thermogenesis and appetite suppression.
    Hursel R; van der Zee L; Westerterp-Plantenga MS
    Br J Nutr; 2010 Mar; 103(5):775-80. PubMed ID: 19874634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Pomegranate Juice on Cardiovascular Risk Factors in Patients with Metabolic Syndrome: a Double-Blinded, Randomized Crossover Controlled Trial.
    Moazzen H; Alizadeh M
    Plant Foods Hum Nutr; 2017 Jun; 72(2):126-133. PubMed ID: 28303364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dietary changes on distinct components of the metabolic syndrome in a young Sri Lankan population at high risk of CVD.
    Guess N; Wijesuriya M; Vasantharajah L; Gulliford M; Viberti G; Gnudi L; Karalliedde J
    Br J Nutr; 2016 Aug; 116(4):719-27. PubMed ID: 27358019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
    Deedwania PC; Shepherd J; Breazna A; DeMicco DA;
    Diabetes Obes Metab; 2016 Jan; 18(1):56-63. PubMed ID: 26434404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.